[go: up one dir, main page]

UY29301A1 - Derivados amida - Google Patents

Derivados amida

Info

Publication number
UY29301A1
UY29301A1 UY29301A UY29301A UY29301A1 UY 29301 A1 UY29301 A1 UY 29301A1 UY 29301 A UY29301 A UY 29301A UY 29301 A UY29301 A UY 29301A UY 29301 A1 UY29301 A1 UY 29301A1
Authority
UY
Uruguay
Prior art keywords
halogen
trifluoromethyl
alkyl
amida
derivatives
Prior art date
Application number
UY29301A
Other languages
English (en)
Inventor
Ian Alun Nash
Kenneth Mark Page
Paul Allen Bethel
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0428326A external-priority patent/GB0428326D0/en
Priority claimed from GB0507513A external-priority patent/GB0507513D0/en
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of UY29301A1 publication Critical patent/UY29301A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/24—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Hospice & Palliative Care (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • AIDS & HIV (AREA)
  • Vascular Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La invención se refiere a un compuesto de la fórmula I en donde m es 0-2 y cada R1 es un grupo tal como hidroxi, halógeno, trifluorometilo, heterociclilo y heterocicliloxi; R2 es halógeno, trifluorometilo o alquilo (1-6C); R3 es hidrógeno, halógeno o alquilo (1-6C); y R4 es cicloalquilo (3-6C); o sales farmacéuticamente aceptables del mismo, procesos para su preparación, composiciones farmacéuticas que lo contienen y su uso en el tratamiento de enfermedades o condiciones médicas mediadas por citoquinas.
UY29301A 2004-12-24 2005-12-22 Derivados amida UY29301A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0428326A GB0428326D0 (en) 2004-12-24 2004-12-24 Amide derivatives
GB0507513A GB0507513D0 (en) 2005-04-14 2005-04-14 Amide derivatives

Publications (1)

Publication Number Publication Date
UY29301A1 true UY29301A1 (es) 2006-07-31

Family

ID=35840517

Family Applications (1)

Application Number Title Priority Date Filing Date
UY29301A UY29301A1 (es) 2004-12-24 2005-12-22 Derivados amida

Country Status (20)

Country Link
US (1) US7786115B2 (es)
EP (1) EP1831174B1 (es)
JP (1) JP4937135B2 (es)
KR (1) KR20070095911A (es)
CN (1) CN102516170A (es)
AR (1) AR055017A1 (es)
AT (1) ATE500227T1 (es)
AU (1) AU2005317868B2 (es)
BR (1) BRPI0519287A2 (es)
CA (1) CA2589764A1 (es)
DE (1) DE602005026703D1 (es)
IL (1) IL183657A (es)
MX (1) MX2007007424A (es)
MY (1) MY140868A (es)
NO (1) NO20073730L (es)
NZ (1) NZ555768A (es)
RU (1) RU2396259C2 (es)
TW (1) TWI364415B (es)
UY (1) UY29301A1 (es)
WO (1) WO2006067444A1 (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2929331B2 (ja) * 1990-07-18 1999-08-03 丸善石油化学株式会社 トラクションドライブ用流体
GB0324790D0 (en) * 2003-10-24 2003-11-26 Astrazeneca Ab Amide derivatives
GB0504019D0 (en) * 2005-02-26 2005-04-06 Astrazeneca Ab Amide derivatives
GB0516570D0 (en) * 2005-08-12 2005-09-21 Astrazeneca Ab Amide derivatives
WO2007149031A1 (en) * 2006-06-19 2007-12-27 Astrazeneca Ab Isoquinoline derivatives and their use as inhibitors of cytokine mediated diseases
US20080070918A1 (en) * 2006-08-24 2008-03-20 Huang Kenneth H Dihydropyridazine, Tetrahydropyridine, Chromanone, and Dihydronaphthalenone Derivatives
BRPI0809011A8 (pt) 2007-03-20 2019-01-15 Celgene Corp composto, composição farmacêutica, método de tratamento, controle ou prevenção de uma doença ou distúrbio, e, forma de dosagem unitária única
TW200845988A (en) * 2007-04-05 2008-12-01 Astrazeneca Ab New compounds and their uses 707
NZ586916A (en) * 2008-02-05 2012-06-29 Hoffmann La Roche Novel pyridinones and pyridazinones
ES2357682T3 (es) 2008-03-25 2011-04-28 Affectis Pharmaceuticals Ag Antagonistas de p2x7r novedosos y su utilización.
AR073711A1 (es) * 2008-10-01 2010-11-24 Astrazeneca Ab Derivados de isoquinolina
US8299077B2 (en) * 2009-03-02 2012-10-30 Roche Palo Alto Llc Inhibitors of Bruton's tyrosine kinase
DK2243772T3 (da) 2009-04-14 2012-02-13 Affectis Pharmaceuticals Ag Hidtil ukendte P2X7R-antagonister og deres anvendelse
WO2011010131A1 (en) 2009-07-21 2011-01-27 Astrazeneca Ab Compositions comprising an oxoisoquinoline methylbenzamide and a polymer
BR112012010752B1 (pt) * 2009-11-05 2021-07-20 University Of Notre Dame Du Lac Compostos imidazo[1,2-a]piridina
CN102858741A (zh) 2010-05-14 2013-01-02 阿费克蒂斯制药股份公司 制备p2x7r拮抗剂的新方法
WO2012110190A1 (en) 2011-02-17 2012-08-23 Affectis Pharmaceuticals Ag Novel p2x7r antagonists and their use
DK2686303T3 (en) 2011-03-18 2016-03-29 Bayer Ip Gmbh N- (3-carbamoylphenyl) -1 H -pyrazole-5-carboxamide derivatives and their use for controlling animal pests
WO2012163456A1 (en) 2011-05-27 2012-12-06 Affectis Pharmaceuticals Ag Novel p2x7r antagonists and their use
WO2012163792A1 (en) 2011-05-27 2012-12-06 Affectis Pharmaceuticals Ag Novel p2x7r antagonists and their use
EP3317277B1 (en) 2015-07-01 2021-01-20 Crinetics Pharmaceuticals, Inc. Somatostatin modulators and uses thereof
EP3658560A4 (en) 2017-07-25 2021-01-06 Crinetics Pharmaceuticals, Inc. SOMATOSTAT IN MODULATORS AND USES THEREOF

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5136461A (en) * 1974-09-24 1976-03-27 Grelan Pharmaceutical Co 44 * 22 isokarubosuchiririiru * fuenirusakusanruinoseizoho
JPS5143766A (en) * 1974-10-09 1976-04-14 Grelan Pharmaceutical Co 44 * 22 * 3*44 jihidoroisokarubosuchiririiru * * fuenirusakusanruino seizoho
ZA924666B (en) * 1991-06-27 1993-12-24 Takeda Chemical Industries Ltd Heterocyclic compounds, their production and use
DE69329787T2 (de) * 1992-09-28 2001-06-13 Hoechst Ag Antiarrhythmische und cardioprotektive substituierte 1(2H)-Isochinoline, Verfahren zu deren Herstellung, diese enthaltende Arzneimittel und ihre Anwendung für die Herstellung eines Arzneimittels zur Behandlung von Herzinsuffizienzen
BR0009083B1 (pt) * 1999-03-17 2011-11-01 derivado de amida compreendendo um núcleo de quinazolinona, processo para a preparação de um derivado de amida, composição farmacêutica, e, uso de um derivado de amida.
JP2002220386A (ja) * 2000-10-02 2002-08-09 Tanabe Seiyaku Co Ltd ベンジルアミン誘導体、その製法およびその合成中間体
GB0504019D0 (en) 2005-02-26 2005-04-06 Astrazeneca Ab Amide derivatives
GB0516570D0 (en) 2005-08-12 2005-09-21 Astrazeneca Ab Amide derivatives

Also Published As

Publication number Publication date
EP1831174B1 (en) 2011-03-02
WO2006067444A1 (en) 2006-06-29
HK1106245A1 (en) 2008-03-07
US7786115B2 (en) 2010-08-31
TW200635901A (en) 2006-10-16
MY140868A (en) 2010-01-29
ATE500227T1 (de) 2011-03-15
AR055017A1 (es) 2007-08-01
DE602005026703D1 (de) 2011-04-14
BRPI0519287A2 (pt) 2009-01-06
JP2008525405A (ja) 2008-07-17
KR20070095911A (ko) 2007-10-01
CN102516170A (zh) 2012-06-27
EP1831174A1 (en) 2007-09-12
CA2589764A1 (en) 2006-06-29
NZ555768A (en) 2009-12-24
AU2005317868A1 (en) 2006-06-29
US20080146566A1 (en) 2008-06-19
IL183657A0 (en) 2007-09-20
RU2396259C2 (ru) 2010-08-10
RU2007130153A (ru) 2009-02-20
IL183657A (en) 2012-10-31
AU2005317868B2 (en) 2009-06-04
JP4937135B2 (ja) 2012-05-23
NO20073730L (no) 2007-09-10
TWI364415B (en) 2012-05-21
MX2007007424A (es) 2007-07-17

Similar Documents

Publication Publication Date Title
UY28578A1 (es) Derivados de amida
UY29301A1 (es) Derivados amida
AR075729A1 (es) Derivados de benzofuranilo, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de la obesidad y/o diabetes.
UY32462A (es) Derivados de bifenilo novedosos para el tratamiento de infección por virus de hepatitis c 644
CY1118969T1 (el) Ενωσεις πυριμιδινο-2-αμινης και η χρηση τους ως αναστολεις των κινασων jak
MX2019010354A (es) Derivado de heteroaril[4,3-c]pirimidina-5-amina, metodo de preparacion del mismo y usos medicos del mismo.
SE0402735D0 (sv) Novel compounds
AR078786A1 (es) Derivados de la cromenona
AR078157A1 (es) Derivados de pirazol-[4,5-d]pirrolo[2,3-b]piridina inhibidores de tirosinquinasas jak 2, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento del cancer
NI200700270A (es) Derivados benzodioxano y benzodioxolano y usos de los mismos
AR078622A1 (es) Piperidinas sustituidas que aumentan la actividad de p53 y sus usos
AR063602A1 (es) Derivados de espiroindolinona, formulaciones farmaceuticas que los contienen y su uso en la obtencion de un medicamento para el tratamiento de trastornos oncologicos.
CR20110617A (es) Derivados aminobutíricos sustituidos como inhibidores de neprilisina
AR059957A1 (es) DERIVADOS DE ESPIROINDOLINONA, MÉTODOS PARA SU PREPARACIoN, UNA COMPOSICIoN FARMACÉUTICA QUE LOS CONTIENE Y SU USO EN LA FABRICACIoN DE MEDICAMENTOS PARA EL TRATAMIENTO DEL CÁNCER.
BR112014023384A2 (pt) inibidores de bace de di-hidro-tiazina e di-hidro-oxazina espirocíclicos, e composições e usos dos mesmos
NO20090723L (no) Kondenserte heterosykliske derivater og fremgangsmater for anvendelse
NI201200044A (es) Compuestos de dióxido de iminotiadiazina como inhibodores de bace , composiciones y su uso
GB0612423D0 (en) Therapeutic agents
CO2022012884A2 (es) Compuestos de amino pirimidina fusionados
AR086100A1 (es) Compuestos de cromenona y composiciones farmaceuticas que los contienen
AR046959A1 (es) Morfolinilo que contiene bencimidazoles como inhibidores de la replicacion del virus sincitial respiratorio
PE20141553A1 (es) Compuestos de triazolopiridina como inhibidores de la ped10a
ECSP088257A (es) Derivados de amida
DE602006006712D1 (de) Thiazolylpiperidin-derivate nützlich als h3 rezeptor modulatoren
DE602007001463D1 (de) Pyrimidin-, chinazolin-, pteridin- und triazinderivate

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20160606